Literature DB >> 9873421

Peptide-based inhibitors of the hepatitis C virus serine protease.

M Llinàs-Brunet1, M Bailey, G Fazal, S Goulet, T Halmos, S Laplante, R Maurice, M Poirier, M A Poupart, D Thibeault, D Wernic, D Lamarre.   

Abstract

Hexapeptide DDIVPC-OH is a competitive inhibitor of the hepatitis C virus (HCV) NS3 protease complexed with NS4A cofactor peptide. This hexapeptide corresponds to the N-terminal cleavage product of an HCV dodecapeptide substrate derived from the NS5A/5B cleavage site. Structure-activity studies on Ac-DDIVPC-OH revealed that side chains of the P4, P3 and P1 residues contribute the most to binding and that the introduction of a D-amino acid at the P5 position improves potency considerably. Furthermore, there is a strong preference for cysteine at the P1 position and conservative replacements, such as serine, are not well tolerated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873421     DOI: 10.1016/s0960-894x(98)00299-6

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

1.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.

Authors:  Annarita Casbarra; Fabrizio Dal Piaz; Paolo Ingallinella; Stefania Orrù; Piero Pucci; Antonello Pessi; Elisabetta Bianchi
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

3.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.

Authors:  Keith P Romano; Akbar Ali; William E Royer; Celia A Schiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-17       Impact factor: 11.205

4.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

Review 5.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

Review 6.  Taming a beast: lessons from the domestication of hepatitis C virus.

Authors:  Joseph M Luna; Mohsan Saeed; Charles M Rice
Journal:  Curr Opin Virol       Date:  2019-03-12       Impact factor: 7.090

7.  Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.

Authors:  Peter W White; Montse Llinàs-Brunet; Ma'an Amad; Richard C Bethell; Gordon Bolger; Michael G Cordingley; Jianmin Duan; Michel Garneau; Lisette Lagacé; Diane Thibeault; George Kukolj
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

8.  In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Authors:  Caterina Trozzi; Linda Bartholomew; Alessandra Ceccacci; Gabriella Biasiol; Laura Pacini; Sergio Altamura; Frank Narjes; Ester Muraglia; Giacomo Paonessa; Uwe Koch; Raffaele De Francesco; Christian Steinkuhler; Giovanni Migliaccio
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

Authors:  Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Maurice; Peter W White; Daniel Lamarre
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.

Authors:  Liangjun Lu; Tami J Pilot-Matias; Kent D Stewart; John T Randolph; Ron Pithawalla; Wenping He; Peggy P Huang; Larry L Klein; Hongmei Mo; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.